# An Interventional Study of Infigratinib in Children With Hypochondroplasia

> **NCT06873035** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **QED Therapeutics, a BridgeBio company** · enrollment: 24 (estimated)

## Conditions studied

- Hypochondroplasia

## Interventions

- **DRUG:** infigratinib 0.128 mg/kg/day
- **DRUG:** infigratinib 0.25 mg/kg/day

## Key facts

- **NCT ID:** NCT06873035
- **Lead sponsor:** QED Therapeutics, a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-22
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06873035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06873035, "An Interventional Study of Infigratinib in Children With Hypochondroplasia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06873035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*